Eosinophilic Fasciitis after Covid Infection: A Case Report and Review of Literature

Eosinophilic fasciitis (EF) is a rare fibrosing disorder caused by an autoimmune response to an unknown trigger. Many possible triggers have been suggested including strenuous exercise, drug or chemical exposure, and preceding infection. We present a case of a female patient, age 69 years, who developed EF following SARS-CoV-2 infection. There have been several advances in the diagnosis and management of EF since it was first described 50 years ago. EF is a mimic of scleroderma, but key clinical features can be used to differentiate between the two diagnoses. Laboratory abnormalities include eosinophilia, elevated inflammatory markers, and hypergammaglobulinemia. A full thickness biopsy of the skin including muscle and fascia is recommended to confirm the diagnosis. Imaging modalities such as ultrasound and magnetic resonance imaging have been increasingly used in the diagnosis and follow-up of EF. Corticosteroids remain the first line in treatment of EF. Combination of steroids and methotrexate have shown the best possible outcome. Early diagnosis is important for better treatment response.

Authors

Institutions

Publication Details

Journal
Clinical Medicine & Research
Published
2025-08-01
DOI
https://doi.org/10.3121/cmr.2025.1907
Primary Topic
Eosinophilic Disorders and Syndromes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Eosinophilic Fasciitis after Covid Infection: A Case Report and Review of Literature

Jonathan E. Cutlan, Sweta Boban, Hiral Patel, Boban Mathew et al.
Clinical Medicine & Research
Eosinophilic Disorders and Syndromes
article

Eosinophilic Fasciitis after Covid Infection: A Case Report and Review of Literature

Jonathan E. Cutlan, Sweta Boban, Hiral Patel, Boban Mathew, Lisa Francis
article en

Abstract

Eosinophilic fasciitis (EF) is a rare fibrosing disorder caused by an autoimmune response to an unknown trigger. Many possible triggers have been suggested including strenuous exercise, drug or chemical exposure, and preceding infection. We present a case of a female patient, age 69 years, who developed EF following SARS-CoV-2 infection. There have been several advances in the diagnosis and management of EF since it was first described 50 years ago. EF is a mimic of scleroderma, but key clinical features can be used to differentiate between the two diagnoses. Laboratory abnormalities include eosinophilia, elevated inflammatory markers, and hypergammaglobulinemia. A full thickness biopsy of the skin including muscle and fascia is recommended to confirm the diagnosis. Imaging modalities such as ultrasound and magnetic resonance imaging have been increasingly used in the diagnosis and follow-up of EF. Corticosteroids remain the first line in treatment of EF. Combination of steroids and methotrexate have shown the best possible outcome. Early diagnosis is important for better treatment response.

Clinical Medicine & ResearchVol. 23(2)
University of North Dakota (US), Marshfield Clinic (US)
Openalex Percentile: Top 68%
Eosinophilic Disorders and Syndromes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Eosinophilic Fasciitis after Covid Infection: A Case Report and Review of Literature — Jonathan E. Cutlan, Sweta Boban, et al. · Clinical Medicine & Research (2025) | TGRS Research Map | TGRS